FDA Lifts Neflamapimod Exposure Cap, Paving Way for Higher-Dose 100 mg BID Regimen
CRVO sits 23% above its 52-week low of $2.13.
Summary
FDA removal of the neflamapimod exposure limit, a new 50 mg tablet with a BID-friendly PK profile, and plans to advance a 100 mg twice-daily regimen expected to raise trough drug concentrations by ~33% were announced by CervoMed.
Key Events · Product Development and Regulatory · CRVO
-
FDA Removes Exposure Limit
The FDA removed the plasma drug exposure limit for neflamapimod after a 39-week dog toxicology study showed a NOAEL three-fold higher than prior studies and more than 30-fold above clinically active exposure levels.
-
New 50 mg Tablet Formulation
A new 50 mg tablet uses the most stable crystalline form, with ~20% lower Cmax and ~20% higher Ctrough versus the prior 40 mg capsule, better suited for twice-daily dosing.
-
100 mg BID Regimen Planned
PK modeling indicates the planned 100 mg twice-daily regimen will increase trough plasma drug concentrations by approximately 33% relative to the 40 mg TID regimen used in Phase 2a and Phase 2b extension.
-
Manufacturing Risk Reduced
A controlled manufacturing process has been implemented for reproducible, large-scale tablet production, addressing CMC variability seen with the 40 mg capsule in the Phase 2b RewinD-LB study.
Analysis · CRVO · Life Sciences
Removing the plasma drug exposure limit eliminates a key constraint on neflamapimod dosing, enabling a higher-dose 100 mg twice-daily regimen. PK modeling projects roughly 33% higher trough concentrations than the prior 40 mg TID regimen — the exposure metric most closely tied to clinical activity in prior trials. This de-risks the program's clinical execution and manufacturing path as CervoMed seeks a strategic partner for Phase 3 in DLB, against a backdrop of going-concern risk and an urgent need for capital.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRVO was trading at $2.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.4M. The 52-week trading range was $2.13 to $10.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.